Cargando…

Severe CIDP-MGUS responsive to Rituximab

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a relatively rare disease with progressive limb weakness and sensory loss. A few patients show a severely progressing course without major response to intravenous immunoglobulin or plasma exchange therapy. CIDP-MGUS (monoclonal gammopathy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Posa, Andreas, Emmer, Alexander, Kornhuber, Malte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306592/
https://www.ncbi.nlm.nih.gov/pubmed/32596526
http://dx.doi.org/10.1016/j.heliyon.2020.e04230
_version_ 1783548686329970688
author Posa, Andreas
Emmer, Alexander
Kornhuber, Malte
author_facet Posa, Andreas
Emmer, Alexander
Kornhuber, Malte
author_sort Posa, Andreas
collection PubMed
description Chronic inflammatory demyelinating polyneuropathy (CIDP) is a relatively rare disease with progressive limb weakness and sensory loss. A few patients show a severely progressing course without major response to intravenous immunoglobulin or plasma exchange therapy. CIDP-MGUS (monoclonal gammopathy of undetermined significance) is a seldom CIDP variant that has been rarely addressed in therapeutic studies. In the presented CIDP-MGUS case, B cell depletion with rituximab had a favourable effect on the disease course, clinically and in nerve conduction studies.
format Online
Article
Text
id pubmed-7306592
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-73065922020-06-25 Severe CIDP-MGUS responsive to Rituximab Posa, Andreas Emmer, Alexander Kornhuber, Malte Heliyon Article Chronic inflammatory demyelinating polyneuropathy (CIDP) is a relatively rare disease with progressive limb weakness and sensory loss. A few patients show a severely progressing course without major response to intravenous immunoglobulin or plasma exchange therapy. CIDP-MGUS (monoclonal gammopathy of undetermined significance) is a seldom CIDP variant that has been rarely addressed in therapeutic studies. In the presented CIDP-MGUS case, B cell depletion with rituximab had a favourable effect on the disease course, clinically and in nerve conduction studies. Elsevier 2020-06-18 /pmc/articles/PMC7306592/ /pubmed/32596526 http://dx.doi.org/10.1016/j.heliyon.2020.e04230 Text en © 2020 The Authors. Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Posa, Andreas
Emmer, Alexander
Kornhuber, Malte
Severe CIDP-MGUS responsive to Rituximab
title Severe CIDP-MGUS responsive to Rituximab
title_full Severe CIDP-MGUS responsive to Rituximab
title_fullStr Severe CIDP-MGUS responsive to Rituximab
title_full_unstemmed Severe CIDP-MGUS responsive to Rituximab
title_short Severe CIDP-MGUS responsive to Rituximab
title_sort severe cidp-mgus responsive to rituximab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306592/
https://www.ncbi.nlm.nih.gov/pubmed/32596526
http://dx.doi.org/10.1016/j.heliyon.2020.e04230
work_keys_str_mv AT posaandreas severecidpmgusresponsivetorituximab
AT emmeralexander severecidpmgusresponsivetorituximab
AT kornhubermalte severecidpmgusresponsivetorituximab